Nitrendipine is a dihydropyridine calcium channel blocker used primarily in the treatment of hypertension. It was developed in the 1980s and introduced into clinical use as part of the expanding class of calcium channel blockers designed to manage cardiovascular disease by reducing vascular resistance.
Its history is marked by its effectiveness in lowering blood pressure through peripheral vasodilation, making it useful in the management of essential hypertension and, in some cases, angina. Nitrendipine works by selectively inhibiting L-type calcium channels in vascular smooth muscle, leading to relaxation of arterial walls and reduced systemic vascular resistance. It has been used in long-term antihypertensive therapy and contributed to the development of later dihydropyridine agents with improved pharmacokinetic profiles.
BRAND NAMES
Baypress (most widely recognized brand in several countries)
Nitrendil (used in some European and Asian markets)
Nitrendipine Tablets (generic-branded formulations available in multiple regions)
MECHANISM OF ACTION
Nitrendipine is a dihydropyridine calcium channel blocker that works by selectively inhibiting L-type voltage-gated calcium channels in vascular smooth muscle. By blocking calcium influx into these cells, it prevents calcium-dependent contraction, leading to relaxation of arterial smooth muscle and vasodilation, particularly in peripheral arteries.
PHARMACOKINETICS
Absorption
Nitrendipine is well absorbed after oral administration, but it undergoes significant first-pass metabolism in the liver, which reduces its systemic bioavailability. Food may increase absorption slightly, but overall effect is variable. Peak plasma concentrations are typically reached within 1 to 2 hours after oral dosing.
Distribution
Nitrendipine is highly lipophilic, allowing good distribution into vascular tissues. It is strongly bound to plasma proteins (>95%), mainly albumin and lipoproteins, which limits the free active fraction in circulation. Its volume of distribution is moderate, reflecting extensive tissue uptake.
Metabolism
Nitrendipine is extensively metabolized in the liver, primarily by cytochrome P450 enzymes (especially CYP3A4). It undergoes oxidative biotransformation into inactive metabolites, which do not contribute to pharmacological activity.
Elimination
The drug is eliminated mainly through renal excretion of inactive metabolites, with a smaller portion eliminated via feces. The elimination half-life is relatively short, approximately 8–12 hours, which supports once or twice daily dosing depending on formulation.
PHARMACODYNAMICS
Nitrendipine acts by blocking L-type calcium channels in vascular smooth muscle, reducing calcium influx. This leads to arterial vasodilation, decreased peripheral vascular resistance, and ultimately a reduction in blood pressure. It has minimal direct effects on cardiac conduction or contractility due to its vascular selectivity.
ADMINISTRATION
Nitrendipine is administered orally in tablet form, typically once or twice daily depending on clinical response. It is commonly used in the management of essential hypertension, and dosing is adjusted based on blood pressure control.
DOSAGE AND STRENGTH
Usual adult doses range from 10–40 mg per day, often started at a lower dose and titrated upward based on blood pressure response and tolerance.
DRUG INTERACTIONS
CYP3A4 inhibitors (e.g., azole antifungals, macrolides) → increased drug levels and risk of hypotension
CYP3A4 inducers (e.g., rifampicin, carbamazepine) → reduced effectiveness
Other antihypertensives → additive blood pressure–lowering effects
Grapefruit juice → can increase plasma concentration and enhance effects
FOOD INTERACTIONS
Food has minimal effect on overall absorption, but grapefruit juice should be avoided due to CYP3A4 inhibition, which can significantly increase drug levels and risk of adverse effects.
CONTRAINDICATIONS
Hypersensitivity to dihydropyridine calcium channel blockers
Severe hypotension
Cardiogenic shock
Unstable angina or acute myocardial infarction (in some clinical settings)
SIDE EFFECTS
Headache
Flushing
Dizziness
Peripheral edema (ankle swelling)
Palpitations
Fatigue
OVER DOSAGE
Overdose of nitrendipine primarily results in excessive vasodilation due to profound blockade of L-type calcium channels in vascular smooth muscle. The most important clinical manifestation is severe hypotension, which may be accompanied by dizziness, weakness, flushing, headache, and syncope. In response to low blood pressure, reflex tachycardia may occur as the body attempts to maintain cardiac output.
TOXICITY
Overdose may lead to severe hypotension, reflex tachycardia, dizziness, and potential cardiovascular collapse in extreme cases. Management is mainly supportive, including blood pressure stabilization, IV fluids, and vasopressor support if needed.
